Concepedia

Author

Jeffrey Sevigny

Columbia UniversityORCID

Also Known As

J Sevigny, J Sévigny, J. J. Sevigny, J. Sevigny, Jeffrey J. Sevigny, Jeffrey Joseph Sevigny, Jeffrey Sevigny

27

Publications

1.4K

Citations

11

H-Index

11

Concepts

All Affiliations

Columbia UniversityMerck & Co., Inc., Rahway, NJ, USA (United States)University of RochesterJohns Hopkins University
JS

About

Jeffrey Sevigny is an author at Columbia University specializing in cognitive performance, rehabilitation, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

24

2

Medicine

1

1

24

3

Geriatrics

1

1

24

4

Neurology

1

1

24

5

Psychiatry

1

1

24

Jeffrey Sevigny

×

9

Publications

815

Citations

9

H-Index

YearCitations

Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia

Jeffrey Sevigny, Steven M. Albert, Michael McDermott,

Neurology

2004

204

Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II

Chris Chatham, Kirsten I. Taylor, Tony Charman,

Autism Research

2017

167

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD

Scott Schobel, Giuseppe Palermo, Peggy Auinger,

Neurology

2017

151

An Evaluation of Neurocognitive Status and Markers of Immune Activation as Predictors of Time to Death in Advanced HIV Infection

Jeffrey Sevigny, Steven M. Albert, Michael McDermott,

Archives of Neurology

2007

108

Growth hormone secretagogue MK-677

Jeffrey Sevigny, Jillian Ryan, C H van Dyck,

Neurology

2008

84

Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results

Jeffrey Sevigny, Olga Uspenskaya, Laura D. Heckman,

Nature Medicine

2024

51

Review: Item Analysis of ADAS-Cog: Effect of Baseline Cognitive Impairment in a Clinical AD Trial

Jeffrey Sevigny, Yahong Peng, Lian Liu,

American Journal of Alzheimer s Disease & Other Dementias®

2009

24

HIV encephalitis simulating Huntington's disease

Jeffrey Sevigny, Steven S. Chin, Yvonne Milewski,

Movement Disorders

2005

15

Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003)

Vissia Viglietta, John O’Gorman, Leslie Williams,

Neurology

2016

11

Page 1